Multidrug Combinations Against SARS-CoV-2 Using GS-441524 or Ivermectin with Molnupiravir And/or Nirmatrelvir in Reconstituted Human Nasal Airway Epithelia

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2024 Oct 26

PMID 39458594

Authors

Denise Siegrist

Hulda R Jonsdottir

Mendy Bouveret

Bernadett Boda

Samuel Constant

Olivier B Engler

Affiliations

Soon will be listed here.

Abstract

The emergence, global spread, and persistence of SARS-CoV-2 resulted in an unprecedented need for effective antiviral drugs. Throughout the pandemic, various drug development and treatment strategies were adopted, including repurposing of antivirals designed for other viruses along with a multitude of other drugs with varying mechanisms of action (MoAs). Furthermore, multidrug treatment against COVID-19 is an ongoing topic and merits further investigation. We assessed the efficacy of multidrug treatment against SARS-CoV-2 in reconstituted human nasal epithelia, using combinations of molnupiravir and nirmatrelvir as a baseline, adding suboptimal concentrations of either GS-441524 or ivermectin, attempting to increase overall antiviral activity while lowering the overall therapeutic dose. Nirmatrelvir combined with molnupiravir, GS-441524, or ivermectin at suboptimal concentrations show increased antiviral activity compared to single treatment. No triple combinations showed improved inhibition of SARS-CoV-2 replication beyond what was observed for double treatments. In general, we observed that the addition of a third compound is not beneficial for antiviral activity, while various double combinations exhibit increased antiviral activity over single treatment.

References

Tanimoto T, Tada S, Fujita S, Hirakawa T, Matsumura M, Isoyama S . Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study. Respir Investig. 2022; 60(3):418-424. PMC: 8898743. DOI: 10.1016/j.resinv.2022.02.004. View

Jayk Bernal A, Gomes da Silva M, Musungaie D, Kovalchuk E, Gonzalez A, Delos Reyes V . Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2021; 386(6):509-520. PMC: 8693688. DOI: 10.1056/NEJMoa2116044. View

Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I . Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A. 2020; 117(13):7001-7003. PMC: 7132130. DOI: 10.1073/pnas.2002589117. View

Wiszniewski L, Jornot L, Dudez T, Pagano A, Rochat T, Lacroix J . Long-term cultures of polarized airway epithelial cells from patients with cystic fibrosis. Am J Respir Cell Mol Biol. 2005; 34(1):39-48. DOI: 10.1165/rcmb.2005-0161OC. View

Orth H, Flasshove C, Berger M, Hattenhauer T, Biederbick K, Mispelbaum R . Early combination therapy of COVID-19 in high-risk patients. Infection. 2023; 52(3):877-889. PMC: 11142969. DOI: 10.1007/s15010-023-02125-5. View

Owen D, Allerton C, Anderson A, Aschenbrenner L, Avery M, Berritt S . An oral SARS-CoV-2 M inhibitor clinical candidate for the treatment of COVID-19. Science. 2021; 374(6575):1586-1593. DOI: 10.1126/science.abl4784. View

Rong L, Dahari H, Ribeiro R, Perelson A . Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med. 2010; 2(30):30ra32. PMC: 3033690. DOI: 10.1126/scitranslmed.3000544. View

Naggie S, Muir A . Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs. Annu Rev Med. 2016; 68:345-358. DOI: 10.1146/annurev-med-052915-015720. View

Cory T, Emmons R, Yarbro J, Davis K, Pence B . Metformin Suppresses Monocyte Immunometabolic Activation by SARS-CoV-2 Spike Protein Subunit 1. Front Immunol. 2021; 12:733921. PMC: 8631967. DOI: 10.3389/fimmu.2021.733921. View

10.

Zaidi A, Dehgani-Mobaraki P . The mechanisms of action of ivermectin against SARS-CoV-2-an extensive review. J Antibiot (Tokyo). 2021; 75(2):60-71. PMC: 8688140. DOI: 10.1038/s41429-021-00491-6. View

11.

Martonik D, Parfieniuk-Kowerda A, Starosz A, Grubczak K, Moniuszko M, Flisiak R . Effect of antiviral and immunomodulatory treatment on a cytokine profile in patients with COVID-19. Front Immunol. 2023; 14:1222170. PMC: 10358833. DOI: 10.3389/fimmu.2023.1222170. View

12.

Dai W, Zhang B, Jiang X, Su H, Li J, Zhao Y . Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020; 368(6497):1331-1335. PMC: 7179937. DOI: 10.1126/science.abb4489. View

13.

Kodde C, Timmen F, Hohenstein S, Bollmann A, Bonsignore M, Kuhlen R . Impact of Dexamethasone on the Pathogen Profile of Critically Ill COVID-19 Patients. Viruses. 2023; 15(5). PMC: 10220814. DOI: 10.3390/v15051076. View

14.

Pan H, Peto R, Henao-Restrepo A, Preziosi M, Sathiyamoorthy V, Abdool Karim Q . Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2020; 384(6):497-511. PMC: 7727327. DOI: 10.1056/NEJMoa2023184. View

15.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

16.

Hung I, Lung K, Tso E, Liu R, Chung T, Chu M . Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020; 395(10238):1695-1704. PMC: 7211500. DOI: 10.1016/S0140-6736(20)31042-4. View

17.

Barber R, Harmer D, Coleman R, Clark B . GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. Physiol Genomics. 2005; 21(3):389-95. DOI: 10.1152/physiolgenomics.00025.2005. View

18.

Maas B, Strizki J, Miller R, Kumar S, Brown M, Johnson M . Molnupiravir: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024; 17(2):e13732. PMC: 10851176. DOI: 10.1111/cts.13732. View

19.

Jonsdottir H, Siegrist D, Julien T, Padey B, Bouveret M, Terrier O . Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro. Biomed Pharmacother. 2022; 150:113058. PMC: 9057985. DOI: 10.1016/j.biopha.2022.113058. View

20.

Alvarez J, Moine P, Etting I, Annane D, Larabi I . Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient. Clin Chem Lab Med. 2020; 58(9):1461-1468. DOI: 10.1515/cclm-2020-0612. View